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Abstract
Background: The cell-cell adhesion molecule cadherin-11 is important in embryogenesis and bone morphogenesis, invasion
of cancer cells, lymphangiogenesis, homing of cancer cells to bone, and rheumatoid arthritis. However, very little is known
about the regulation of cadherin-11 expression.
Methodology/Principal Findings: Here we show that cell density and GSK-3b regulate cadherin-11 levels in cancer cells.
Inactivation of GSK3b with lithium chloride or the GSK3 inhibitor BIO and GSK3b knockdown with siRNA repressed cadherin-
11 mRNA and protein levels. RNA Polymerase II chromatin immunoprecipitation experiments showed that inhibition of
GSK3 does not affect cadherin-11 gene transcription. Although the cadherin-11 39UTR contains putative microRNA target
sites and is regulated by Dicer, its stability is not regulated by GSK3 inhibition or density. Our data show that GSK3b
regulates cadherin-11 expression in two ways: first a b-catenin-independent regulation of cadherin-11 steady state mRNA
levels, and second a b-catenin-dependent effect on cadherin-11 39UTR stability and protein translation.
Conclusions: Cadherin-11 mRNA and protein levels are regulated by the activity of GSK3b and a significant degree of this
regulation is exerted by the GSK3 target, b-catenin, at the level of the cadherin-11 39UTR
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Introduction
Cadherin-11, also known as OB-cadherin was first identified in
mouse osteoblasts and is normally expressed in cells with a
mesenchymal phenotype and of mesodermal origin, including the
mesenchyme of the kidney and brain during development [1].
Cadherin-11 is also expressed in cartilage synoviocytes and is an
important mediator of the synoviocyte reaction that characterizes
rheumatoid arthritis [2,3]. The cadherin-11 knockout mouse
exhibits bone and behavioral abnormalities and is resistant to
induction of rheumatoid arthritis [2,3]. Additionally, cadherin-11
is expressed in several types of cancer including breast and prostate
cancers, osteosarcoma, and colon cancer [4–8]. In these cancers
cadherin-11 expression is associated with the most aggressive and
most metastatic cancer cells.
Little is known about the regulation of cadherin-11 expression.
TGFb1 regulates cadherin-11 in cultured extravillous cytotropho-
blasts, and progesterone, but not 17-beta-estradiol, regulates
cadherin-11 in cultured endometrial stromal cells undergoing
decidualization [9,10]. During development cadherin-11 is
expressed in cranial neural crest cells of the developing Xenopus
embryo, and XWnt-8 overexpression increases Xcadherin-11
mRNA in Xenopus animal cap cells [11,12].
The principle pathway associated with canonical Wnt signaling
involves inhibition of GSK3. GSK3 is intricately involved in many
pathways essential to cellular function. Other mechanisms that
also negatively regulate GSK3b include GSK3b phosphorylation
on Ser9 by Akt and inhibition by LiCl treatment and 6-
bromoindirubin-39-oxime (BIO) treatment [18–20]. In the ab-
sence of canonical Wnts, GSK3 binds and phosphorylates b-
catenin, in a multi-protein complex including axin, adenomatous
polyposis coli (APC), and protein phosphatase 2A. Phosphoryla-
tion by GSK3b results in b-catenin protein degradation [13–15].
In the presence of canonical Wnts, activated Disheveled prevents
GSK3-dependent phosphorylation of b-catenin [17].
In this study we use breast cancer cells with low levels of
endogenous activated GSK-3 and b-catenin and prostate cancer
cells with constitutively activated GSK-3 and b-catenin to show
that, GSK3b regulates cadherin-11 expression in two ways. The
first mechanism is through b-catenin-independent regulation of
steady state cadherin-11 mRNA levels. The second mechanism
involves a b-catenin-dependent effect on cadherin-11 39UTR
stability and protein translation.
Results
Cell density and inhibition of GSK3b regulate cadherin-11
mRNA and protein expression
MDA-MB-231 cells, a mesenchymal-like breast cancer cell line
that expresses cadherin-11, have undetectable levels of other
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4797cadherins and low levels of activated b-catenin. In pilot
experiments we noticed that cadherin-11 expression varied
noticeably depending on the number of cells plated. Figure 1
shows that cells grown at higher cell densities had markedly
increased cadherin-11 mRNA (Figure 1A) and protein (Figure 1B)
expression on a per cell basis compared to those grown at low
density. In Xenopus laevis, cadherin-11 is regulated by xWnt8,
although it is not known if the cadherin-11 gene is a direct
transcriptional target or if either the canonical or non-canonical
pathways are involved [11]. To test if the canonical Wnt pathway
regulates cadherin-11 in MDA-MB-231 cells, we treated cells with
lithium chloride (LiCl), an inhibitor of GSK3b. LiCl treatment
repressed cadherin-11 mRNA and protein levels and blocked the
effects of increased cell density (Figure 1A, B). Cadherin-11
protein levels were also inhibited by LiCl in three other cell-lines
(BT549, Hs578t and PC-3 Figure 1C). Remarkably, N-cadherin,
which is endogenously expressed by these cell-lines and not by
MDA-MB-231 cells, was unaffected by LiCl, strongly indicating
that inhibition of GSK3b specifically regulated cadherin-11
expression. If the effects of LiCl are due to transient inhibition
of GSK3b we anticipated that removal of LiCl should reverse its
effects on cadherin 11. Figure 1D shows that this is indeed the case
as cadherin-11 levels returned to control values 12 hours following
LiCl washout. To confirm that the effects of LiCl were related to
inhibition of GSK3b, we treated cells with 6-bromoindirubin-39-
oxime (BIO), a small molecule kinase inhibitor selective for
GSK3a/b (Figure 1E, F). Inhibition of GSK3b with BIO
stabilized b-catenin, and like LiCl, reduced cadherin-11 mRNA
and protein accumulation. Furthermore, siRNA directed against
GSK3b mRNA decreased cadherin-11 protein expression in the
absence of either LiCl or BIO in MDA-MB-231 but not in PC-3
cells (Figure 1G). Therefore, GSK3b knockdown had little effect
on cadherin-11 levels in PC-3 cells (Figure 1G). Unlike MDA-231
cells, PC-3 cells have high levels of nuclear activated b-catenin as a
result of a PTEN mutation and constitutive inactivation of GSK3b
[21]. Consequently, removal of GSK3b in these cells may have
less effect as it is already inactivated.
Recruitment of RNA polymerase II to the cadherin-11
gene is unaffected by
To test if GSK3b regulates cadherin-11 expression at the level
of transcription, MDA-MB-231 cells were treated with the RNA
polymerase II inhibitor, actinomycin D and were compared to the
results of cells treated with LiCl. Figure 2A shows that cadherin-11
mRNA levels declined following either LiCl or actinomycin D
treatment. However, in this experiment, and on other occasions,
we noticed that LiCl treatment repressed cadherin-11 mRNA
levels more rapidly than actinomycin D suggesting an additional
non-transcriptional level of regulation. If the effects of GSK3b
inhibition on cadherin-11 mRNA have a transcriptional compo-
nent, we would anticipate that recruitment of RNA polymerase II
to the cadherin-11 gene to decrease. To test this hypothesis, we
carried out RNA polymerase II chromatin immunoprecipitation
assays (Pol II ChIP) using cadherin-11 specific primers which
amplify a portion of intron 1 (see Materials and Methods).
Figure 2B shows that, as expected, actinomycin D markedly
reduced the amount of Pol II recruited to both GAPDH and the
cadherin-11 gene. However, even though cadherin-11 mRNA
levels are markedly reduced by treatment of cells with BIO
(Figure 1) it did not affect Pol II recruitment to the cadherin-11
gene (Figure 2B). In other experiments we found that members of
the Snail/Slug family, transcriptional repressors known to be
regulated by GSK3b and by b-catenin are not involved in
cadherin-11 repression (Figure S1) [22]. Taken together these
experiments indicate that inhibition of GSK3b by LiCl or BIO
influences cadherin-11 mRNA and protein levels by mechanisms
largely independent of transcriptional repression.
The cadherin-11 39untranslated region (UTR) is highly
conserved and destabilizing in cadherin-11 expressing
cells
In many situations regulation of mRNA stability and its
capacity for translation are mediated by the 39-untranslated
region (UTR). If the cadherin-11 39-UTR is important in the
normal regulation of cadherin-11 expression we might expect it
to be conserved across species. Table 1 shows the percent identity
of the human cadherin-11 and E-cadherin transcripts and 39-
UTRs compared with other species. Remarkably for a region that
is not translated the cadherin-11 39-UTR was almost completely
conserved across species (94% human with mouse). In contrast
the E-cadherin-39UTR is poorly conserved (17% human with
mouse). Analysis of the secondary structure of this region of both
the cadherin-11 and E-cadherin 39UTRs revealed a high degree
of stem loop structures (Figure 3B and Figure 3C). These
observations strongly suggest that the cadherin-11 39UTR has a
conserved regulatory function.
The NCBI database identifies a region of the cadherin 39UTR
which spans approximately 1 kb and includes a traditional poly-A
signal and site. However, the Ensembl database identifies a
cadherin-11 39UTR of roughly 3 kb which includes a second poly
A signal 2363 bp from the stop codon (Figure 3A). The poly-A
signal sequences (AAUAAA) within the 39UTR are bolded in
Figure 3A. Blue highlighted sequences indicate Shaw-Kamens
sequences, also known as AU-rich elements (AREs [Shaw and
Kamen, 1986]). Many microRNA binding elements also exist in
the cadherin-11 39UTR (too numerous to indicate) as determined
by ARGONAUTE 2 and miRanda. To determine the actual
length of the cadherin-11 39UTR, total RNA was isolated from
PC3 metastatic prostate cancer cells (Figure 3D), MDA-MB-231
cells (data not shown), and MRC5 lung fibroblast cells (data not
shown) for analysis. Primers were designed approximately every
500 bp of the Ensembl sequence to make progressively shorter
PCR products. In all three cell lines primers designed to produce a
PCR product of 1451 bp amplify a product, but the primers
designed to make a product of 1952 bp do not (Figure 3D).
Although, this 501bp does not include a poly-A signal or addition
site one does exist at position 2363 indicating that this longer
transcript may be an alternate 39-UTR.
To investigate the function of the cadherin-11 39-UTR, it was
cloned from MDA-MB-231 genomic DNA. A series of stop codons
were included at the 59-end of the construct followed by the DNA
sequence directly 39 to exon 13, the 39-UTR. Both the NCBI and
Ensembl 39UTRs were cloned using the red highlighted primer
sequences in Figure 3A into a luciferase reporter vector and
named luc-CDH11 39UTR NCBI and luc-CDH11 39UTR
Ensembl, respectively.
In cadherin-11 positive PC-3 and MDA-231 cells both luc-
CDH11 39UTR NCBI and luc-CDH11 39UTR Ensembl were
significantly less active than pGL3, which has the SV40 poly A
addition signal and site (Figure 4A). In HEK293 cells which do not
express cadherin-11, luc-CDH11 39UTR Ensembl was more
active than either control vector or luc-CDH11 39UTR NCBI
(Figure 4A). These data indicate that the both cadherin-11
39UTRs confer destabilization properties when expressed in cells
which normally make cadherin-11. In contrast, in HEK293 cells,
which do not normally make cadherin-11, luc-CDH11 39UTR
Ensembl but not luc-CDH11 39UTR NCBI is stabilizing.
Regulation of Cadherin-11
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To investigate if microRNA influenced the activity of luc-
CDH11 39-UTR we knocked down Dicer, which is essential for
the production of microRNAs. Removal of Dicer significantly
increased the activity of luc-CDH11 39-UTR indicating that
microRNAs regulate the endogenous activity of the cadherin-11
39-UTR (Figure 4B). Consistent with a role for miRNA, several
putative miRNA binding sites exist in this region, however, none
of these predicted miRNAs was regulated by inhibition of GSK3b
(Figure S2). These data demonstrate that although miRNAs can
regulate luc-CDH11 39-UTR this is not the mechanism whereby
GSK3b inhibition regulated cadherin-11 mRNA levels. Unlike
siRNAs, which always direct mRNA degradation, miRNAs often
regulate protein translation without affecting mRNA levels [23–
25]. To test this we examined the effects of Dicer knockdown on
cadherin-11 protein and mRNA levels. Figures 4C and 4D show
that even in the face of Dicer knockdown, endogenous cadherin-
11 mRNA and protein levels were unchanged and the repressive
Figure 1. Density increases cadherin-11 and GSK3b inhibitors decrease cadherin-11 expression. A and B: MDA-MB-231 cells were plated
at two densities, 50% and 90% confluency, called low and high, respectively. The cells were allowed to grow overnight in serum-free medium.
24 hours after plating cells were treated with 20 mM NaCl (N) or 20 mM LiCl (L). 24 hours after treatment, RNA and protein were collected for real-
time PCR (A) and Western (B) analysis. C: Cancer cells BT549, Hs578T, PC-3, and Kato-III were plated at a medium density and allowed to adhere. Cells
were then treated with 20 mM LiCl or NaCl control. 48 hours after transfection protein was collected for Western blot analysis. D: MDA-MB-231 cells
were plated at a medium density, serum starved overnight, and treated with 20 mM NaCl or 20 mM LiCl. 24 hours after treatment, the cells were
washed once with PBS and maintained in serum-free medium containing only 20 mM NaCl. RNA was collected at the times indicated for real-time
PCR analysis. E and F: MDA-MB-231 cells were plated at a medium density and serum starved overnight. 16 hours after plating, the cells were treated
with 1 mM meBIO (control), 1 mM BIO, or 20 mM LiCl. RNA (E) or protein (F) was collected at the designated times and analyzed using real-time PCR (E)
and Western blot analysis (F). G: MDA-MB-231 and PC-3 cells were transfected with either non-specific scrambled siRNA (siScramble), or siRNA
directed against GSK3b (si GSK3). 48 hours after transfection protein was isolated for Western blot analysis.
doi:10.1371/journal.pone.0004797.g001
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although the basal activity of the cadherin-11 39UTR is affected by
Dicer knockdown, cadherin-11 mRNA and protein levels are not.
b-catenin regulates the activity of the cadherin-11 39UTR,
steady state mRNA levels and cadherin-11 protein
translation in PC-3 cells
Perhaps the best known substrate of GSK3b is b-catenin and
many studies have shown that Wnt-mediated inhibition of GSK3b
stabilizes and activates cytoplasmic b-catenin [17,26]. Although
the effects of inhibition of GSK3b on cadherin-11 are not
mediated transcriptionally it is possible that stabilization of b-
catenin may repress cadherin-11 mRNA and/or protein levels
using an alternative mechanism. To test this PC-3 cells, which
normally express high levels of activated b-catenin, were
transfected with luc-CDH11 39UTR Ensembl or luc-CDH11
39UTR NCBI and treated with b-catenin siRNA [21]. Like Dicer
knockdown, knockdown of b-catenin significantly increased the
activity/stability of both cadherin-11 39UTR reporters (Figure 5A).
However, in contrast to Dicer knockdown, removal of b-catenin
significantly increased cadherin-11 protein and steady state
mRNA levels in PC-3 cells (Figure 5C).
Discussion
The majority of patients dying from breast or prostate cancer
have metastases to the skeleton. Although bone metastases are
incurable, patients survive several years suffering serious morbid-
ity, including fractures, spinal cord compression, severe bone pain,
and hypercalcemia [5,27]. In the adult, cadherin-11 is strongly
expressed in bone as well as certain metastatic cancers, particularly
those inclined to metastasize to bone [4,6,27]. Once in the bone, it
is possible that these cadherin-11-expressing tumor cells activate
either osteoclasts or osteoblasts, depending on the type of cancer
metastasis, leading to bone remodeling. As the bone is remodeled,
growth factors are released into the matrix further stimulating the
tumor cells by creating a fertile environment for growth. These
changes are reminiscent of those that occur during rheumatoid
arthritis, a disease that is also characterized by an important role
for cadherin-11 in the activated synoviocyte [2,3]. Given its role in
these important diseases we sought to determine how cadherin-11
expression is regulated. In the present study we show that
cadherin-11 mRNA and protein levels are increased by high cell
density and are markedly regulated by the activity of the
ubiquitous serine/threonine kinase GSK3b. Remarkably, a
significant degree of regulation is exerted by the GSK3b target,
b-catenin, at the level of the cadherin-11 39UTR.
A role for GSK3b and b-catenin in cadherin-11 mRNA and
protein homeostasis
The best studied mechanism by which GSK3b is regulated is
Akt-dependent serine phosphorylation. Growth factors, such as
insulin, activate the phosphatidylinositol 3-kinase (PI3K)/Akt
pathway. PI3K converts PIP2 to PIP3, a critical step necessary
for the activation of PKB/Akt. PTEN is a phosphatase commonly
mutated in cancers that is necessary for the dephosphorylation of
PIP3 thereby inhibiting Akt activation. Once activated Akt acts on
many cellular proteins including mTOR, caspase 9, Bad, IKK,
and GSK3b. Akt phosphorylates GSK3b on serine 9 and GSK3a
on serine 21 to inhibit their kinase activity. Understanding GSK3b
regulation by the Akt pathway is important to the present study
because a PTEN mutation in PC-3 prostate cancer cells results in
activated Akt, GSK3b inhibition, and activation of endogenous b-
catenin [28]. Importantly, GSK3b is central to the promotion of
inflammation in various inflammatory diseases including colitis
and arthritis [29,30]. The second well-defined mechanism of
Figure 2. Transcriptional mechanism of cadherin-11 regula-
tion. A: MDA-MB-231 cells were grown at a medium density for
16 hours in the absence of serum. The cells were then pretreated with
5 mg/ml actinomycin D or an equivalent volume of ethanol (untreated).
30 minutes later the cells were treated with either 20 mM NaCl (control)
or LiCl. At the indicated time points, RNA and protein were collect for
real-time PCR analysis. B: MDA-MB-231 cells were treated with 20 mM
NaCl or LiCl for 24 hours. Genomic DNA was then harvested for RNA
polymerase II ChIP analysis followed by PCR specific to GAPDH and
cadherin-11.
doi:10.1371/journal.pone.0004797.g002
Table 1. Untranslated region and coding sequence alignment.
ClustalW Nucleotide Sequence Alignment compared to H. sapiens
Species
E-cadherin protein
coding sequence
E-cadherin
39UTR
Cadherin-11 protein
coding sequence
Cadherin-11
59UTR
Cadherin-11 39UTR
(NCBI)
Cadherin-11 39UTR
(Ensembl)
M. musculus 79 17 89 84 94 85
R. norvegicus 80 27 90 76 94 84
P. troglodytes 99 98 99 98 99 99
G. gallus 64 N/A 80 59 86 68
doi:10.1371/journal.pone.0004797.t001
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PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e4797GSK3b regulation is the canonical Wnt pathway in which
inhibition of GSK3b and stabilization of b-catenin results in
marked changes in gene expression. Although many studies have
observed that Wnt-GSK3b-mediated activation of b-catenin
results in accumulation of nuclear and cytoplasmic b-catenin,
most studies concentrate on the function of b-catenin as a
transcriptional co-activator of TCF, and more recently nuclear
receptors, in the nucleus [31–33]. However, b-catenin has
significant homology to the RNA binding protein pumilio and
several recent studies have pointed to an important role for b-
catenin in post-transcriptional regulation [34]. For example, b-
catenin regulates VEGF-D, cyclooxygenase-2 and cyclin D1
mRNA stability potentially by interaction with their respective
39-UTRs [35-38]. b-catenin can also regulate alternative splicing
of estrogen receptor b (ERb) in colon cancer cells [35–38]. The
ribosome-associated factor eIF6 associates with b-catenin and the
complex may have a role in translational regulation in concert
with miRNAs [39,40]. However, although the endogenous activity
of the cadherin-11 39-UTR is regulated by Dicer, cadherin-11
mRNA and protein regulation by GSK3b are not, ruling out a
role for miRNAs in this process. Our data show that the activity of
the cadherin-11 39-UTR is regulated by b-catenin in cells which
normally express activated b-catenin such as PC-3 prostate cancer
cells. Taken together these data point to an important role for
GSK3b and b-catenin in cadherin-11 mRNA and protein
homeostasis and may lead to the development of therapeutics
for diseases such as, metastatic prostate and breast cancer and
rheumatoid arthritis, that are characterized by elevated cadherin-
11. Indeed inhibition of GSK3b or ablation of the GSK3b gene
ameliorates inflammation dependent arthritis [29].
Materials and Methods
Materials and Reagents
LiCl (L9650), NaCl (S3014), and actinomycin D (A1410) were
obtained from Sigma-Aldrich (Germany), meBIO (361556) and
Figure 4. The stabilizing and destabilizing effects of the cadherin-11 39UTR. A: PC-3, MDA-MB-231, and HEK 293 cells were transfected with
pGL3-Promoter, pGL3-CDH11-39UTR NCBI, or pGL3-CDH11-39UTR Ensembl and pCMV-Renilla. 48 hours after transfection, cells were lysed using
passive lysis buffer and luciferase activity was analyzed. (* indicates a p-value .0.01; ** indicates a p-value .0.001) B: MDA-MB-231 and PC-3 cells
were transfected with pGL3-CDH11 39-UTR and pCMV-Renilla along with either non-specfic siRNA (siScramble) or siRNA directed against Dicer
(siDicer). 48 hours after transfection, cells were lysed using passive lysis buffer and luciferase activity was analyzed. (* indicates a p-value .0.05) C
and D: MDA-MB-231 cells were transfected with non-specific siRNA (siScramble), or siRNA directed against Dicer (si Dicer). Cells were collected for
real-time PCR (C) and Western blot (D) analysis 72 hours after transfection.
doi:10.1371/journal.pone.0004797.g004
Figure 3. In silico evaluation of the cadherin-11 39UTR. A: Sequence of cadherin-11 39-UTR according to the Ensembl database (NM_001797).
Bolded sequences indicate the poly-A signals and site respectively. Blue highlighted sequences indicate Shaw-Kamens, destabilizing sequences. The
first two red highlighted sequences indicate the primers used to design pGL3-CDH11-39UTR NCBI, as denoted by the bracket. The first and last red
highlighted sequences indicate the primers used to design pGL3-CDH11-39UTR Ensembl, as denoted by the bracket. B: Predicted secondary structure
of the Ensembl cadherin-11 39UTR (as predicted by GeneBee). C: Predicted secondary structure of the Ensembl E-cadher 39UTR (as predicted by
GeneBee). D: RT-PCR of PC3 RNA using primers designed approximately every 500 bp.
doi:10.1371/journal.pone.0004797.g003
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11 (5B2H5) from Invitrogen (32-1700, Carlsbad, CA), anti-b-
catenin antibody from BD Biosciences (610154, San Jose, CA),
Dicer antibody from Abcam (ab14601, Cambridge, MA), anti-
GSK3b antibody from Cell Signaling Technologies (9315, Boston,
MA), anti-FLAG (M2) was from Sigma (F3165, Germany), anti-
GAPDH was from Research Diagnostics Inc (TRK5G4-6C5,
Flanders, NJ), anti-Snail (H-130) (sc-28199) antibody from Santa
Cruz. The anti-eIF6 antibody S13 was a generous gift from Dr. Biffo
and generated against a C-terminus peptide of eIF6 [40,41]. Small
interfering RNA (siRNA) reagent (SMART pool) for human
CTNNB1 (M-003482-00), Dicer (M-003483-00), and GSK3b (M-
003010-03), were purchased from Dharmacon (Lafayette, CO).
Non-specific (Scramble) siRNA was generated using forward: (59-
AAGCTCCTATAGCGTATGGTGCCTGTCTC-39) and reverse:
(59-CACCATACGCTATAGGAGCTTCCTGTCTC-39)p r i m -
ers and the Silencer siRNA Construction kit (AM1620, Ambion,
Austin, TX).
Expression Vectors
Plasmid DNA encoding wild type (WT) b-catenin was used as
previously described and DNA encoding wild type Snail was a kind
gift from Dr. Mien-Chie Hung [15,22]. Dominant negative (DN)
Snailwas generatedbyPCR fromthewild type Snail constructusing
primers described in Yamasaki et al. forward: (59-CGGGATCCAC-
TATGGCCTTCAACTGCAAATACTG-39) and reverse: (59-
CGCTCGAGGCGGGGACATCCTGAGCA-39) and cloned into
pCMV-Tag2 (Stratagene, La Jolla, CA) using BamHI and XhoI
restriction sites [42]. Cadherin-11 39-UTR fragment was cloned
from genomic DNA obtained from MDA-MB-231 cells using
Expand High Fidelity PCR System (11732641001, Roche, India-
napolis, IN) according to the manufacturer’s protocol. For
amplification of the CDH11 39UTR NCBI forward:
(59-TGCTAGCTAAGTAAGTAACAATAACGATA-
CAAATTT-39) and reverse:
(59-CCGGATCCACGCGTGAATCTTGTCT-
GAAAAAACATTTG-39) primers were used. For am-
plification of the CDH11 39UTR Ensembl forward:
(59-TGCTAGCTAAGTAAGTAACAATAACGATA-
CAAATTT-39) and reverse:
(59-GGATCCACGCGTGTTCCACCTGACATACA-
GAGCC-39) primers were used. These PCR products
were ligated in place of the SV40 39UTR of pGL3-
Promoter (Promega, Madison, WI).
Cell Culture and Transfection
MDA-MB-231, Hs578T, BT549 breast cancer cells, PC-3
prostate cancer cells, and HEK293 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 5% fetal bovine serum (FBS) in 5% CO2 incubator at 37uC.
All transient transfections of plasmid DNA and siRNA in MDA-
MB-231 and PC-3 cells were performed with Amaxa electropo-
ration system (Amaxa, Inc, Geithersburg, MD) according to the
manufacturer’s protocol. Transient transfections for immunofluo-
rescence were preformed using Lipofectamine 2000 Transfection
Reagent (11668-019, Invitrogen, Carlsbad, CA) and luciferase
analysis using Lipofectamine 2000 (Invitrogen) for PC-3 cells,
ProFection Mammalian Transfection System—Calcium Phos-
phate (E1200, Promega, Madison, WI) for MDA-MB-231 cells,
and FuGENE 6 Transfection Reagent (11814443001, Roche,
Switzerland) for HEK293 cells.
Figure 5. b-catenin as a regulator of cadherin-11 expression. A:
PC-3 cells were transfected with pGL3-CDH11-39UTR NCBI or pGL3-
CDH11-39UTR Ensembl and pCMV-Renilla and along with either non-
specific siRNA or siRNA directed against CTNNB1. 48 hours after
transfection cells were were lysed using passive lysis buffer and
luciferase activity was analyzed. Luciferase activity was normalized to
renilla activity. (** indicates a p-value .0.001). B: MDA-MB-231 and PC-
3 cells were transfected with either non-specific scrambled siRNA
(siScramble) or siRNA directed against CTNNB1 (si b-cat). 24 hours after
transfection cells were treated with 1 mM BIO or meBIO (control).
48 hours after transfection protein was isolated for Western blot
analysis. C: MDA-MB-231 and PC-3 cells were transfected with either
non-specific scrambled siRNA (siScramble) or siRNA directed against
CTNNB1 (si b-cat). 24 hours after transfection cells were treated with
1 mM BIO or meBIO (control). 48 hours after transfection RNA was
isolated for real-time PCR analysis. (* indicates a p-value .0.05; **
indicates a p-value .0.005)
doi:10.1371/journal.pone.0004797.g005
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RNA isolation (mRNA). MDA-MB-231 or PC-3 cells were
incubated in the presence or absence of LiCl (20mM) or BIO
(1 mM) for 24 h. RNA was isolated using Trizol (15596-018,
Invitrogen) combined with RNAeasy (74106, Qiagen, Valencia,
CA) according to the manufacturer’s instructions.
Total RNA isolation (microRNA). MDA-MB-231 cells
incubated in the presence or absence of 20 mM LiCl for
24 hours. Total RNA was isolated using the miRVana RNA
isolation kit (AM1562, Ambion).
Real time quantitative PCR
mRNA. Relative quantitation was used to evaluate the raw
data obtained from real-time PCR (7900 HT real time PCR
system, Applied Biosystems, Foster City, CA). Single-stranded
cDNA was prepared using TaqMan Reverse Transcription
Reagents (N808-0234, Applied Biosystems) following the
manufacturer’s protocol. TaqMan Universal PCR Master Mix
(4304437, Applied Biosystems) was used for all reactions. All
primer/probe mixes (CDH11 Hs00156438_m1, GAPDH
Hs99999905_m1) were obtained from Applied Biosystems and
performed in triplicate. The samples were analyzed using the
delta-delta Ct method of analysis [43]. The final value obtained
was a measure of the fold change in gene expression for the
particular gene of interest between the treated sample and the
untreated sample. Experiments were run in triplicate, and for all
analyses a p-value of ,0.05 was considered to be statistically
significant.
microRNA. cDNA was generated by TaqMan MicroRNA
Reverse Transcription kit (4366596, Applied Bioscience) following
manufacturer’s protocol. Primer/probe mixes specific for each
microRNA (RNU6B, 4373381; hsa-miR-19a, 4373099; hsa-miR-
27a, 4373287; hsa-miR-33, 4373048; hsa-miR-101, 4373159; hsa-
miR-133b, 4373172; hsa-miR-337, 4373044; hsa-miR-424,
4373201) were obtained from Applied Biosystems (Foster City,
CA). TaqMan Universal Master PCR Mix (4304437, Applied
Biosystems) was used for all reactions. All experiments were
performed in triplicate. The average value of the triplicate
readings for each unknown was normalized to the corresponding
value for U6 RNA. The samples were analyzed using the delta-
delta Ct method of analysis [43]. The final value obtained was a
measure of the fold change in gene expression for the particular
gene of interest between the treated sample and the untreated
sample. For all analyses a P-value of ,0.05 was considered to be
statistically significant.
Chromatin immunoprecipitation (ChIP) analysis
One 15 cm tissue culture dishes were plated with 95% confluent
MDA-MB-231 cells for each condition. Cells were treated with
5 mg/ml actinomycin D for 30 minutes in serum-free DMEM. As
specified, cells were incubated with 20 mM NaCl or LiCl for an
additional 24 hours. 37% formaldehyde solution was added to
each plate for a final concentration of 1.5% and incubated at 37uC
for 15 minutes. Plates were washed one time with PBS containing
0.125 M glycine and Complete Mini Protease Inhibitor Cocktail
(11836153001, Roche), and then a second time with PBS plus
inhibitor. Cells were collected and spun for at 2000 rpm, 4uC for
5 minutes. The pellet was resuspended in 1 ml SDS lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1) with
protease inhibitors. Cells were then sonicated using a 15 second
on, 45 second off program 4 times consecutively; then diluted 1:10
in ChIP Dilution Buffer (0.01% SDS, 1.1% Triton X-100,
1.2 mM EDTA, 16.7 mM Tris-HCl, pH .1, 167 mM NaCl) plus
protease inhibitor. The samples were then precleared overnight at
4uC with 75 ml Protein A/G Plus-agarose beads (sc-2003, Santa
Cruz) supplemented with 3 ml 10 mg/ml Sonicated Salmon
Sperm DNA (201190, Stratagene, La Jolla, CA) and 13 ml
1 mg/ml BSA. Samples were then incubated with 10 mg RNA
Polymerase II (N-20) (sc-899, Santa Cruz) overnight, tumbling at
4uC. Add 40 ml Protein A/G Plus-agarose beads for 2 hours
rotating at 4uC. Samples were spun at 1000 rpm for 1 minute,
then washed once with each: Low Salt Immune Complex Wash
Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 150 mM NaCl), High Salt Immune Complex Wash
Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.1, 500 mM NaCl), LiCl Immune Complex Wash
Buffer (0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholic acid,
1 mM EDTA, 10 mM Tris-HCl, pH 8.1), and TE buffer.
Samples were eluted twice in 100 ml in elution buffer (1% SDS,
0.1 M NaHCO3) vortexing for 15 minutes at room temperature.
12 ml 5 M NaCl was added to eluate and incubated at 65uC
overnight. Then 4 ml 0.5 M EDTA, 8 ml 1M Tris-HCl, pH 6.5
and 2 ml of 10 mg/ml proteinase K was added and incubated at
45uC for 1 hour. The samples were cleaned up using the
QIAGEN PCR Clean up kit (QIAGEN). PCR was performed
using TaKaRa Premix Ex Taq kit (RR039, TaKaRa, Otsu, Shiga,
Japan). The final reaction contains: 16Premix Ex Taq, 2.5 mMo f
each primer, 8% DMSO, and 20% processed DNA (or 20% of a
1:10 dilution of input). For amplification of GAPDH, forward: (59-
TACTAGCGGTTTTACGGGCG-39) reverse: (59-TCGAA-
CAGGAGGAGCAGAGAGCGA-39). For amplification of
CDH11,
forward: (59-AAAGCAAAAGGGAGGGAGA-39)
reverse: (59-AGGTACAAACCCCCTCTGCT-39) primers were
used.
Immunoblotting
Cells were treated for the indicated times. Cells were rinsed
once with PBS and lysed with sample buffer (2% SDS, 10%
glycerol, 10 mM Tris, pH 7.5) containing 1 mM sodium ortho-
vanadate, 0.05 M sodium fluoride, and Complete mini protease
inhibitors (11836153001, Roche Applied Science, Indianapolis,
IN). Cell lysates were boiled for 10 minutes. Protein concentration
was determined with a Bio-Rad DC Protein Assay (500-0116, Bio-
Rad, Hercules, CA). After SDS-poly acrylamide gel electropho-
resis, proteins were transferred to Protran BA 83 Nitrocellulose
(10402495, Germany). Membranes were blocked with 5% milk in
Tris-Buffered Saline containing 0.1% Tween-20, and incubated
with primary antibody overnight at 4uC and subsequently with
HRP-labeled secondary antibody. Proteins were visualized with
ECL chemiluminescent reagents (RPN2106, Amersham Biosci-
ences, Piscataway, NJ) or SuperSignal West Femto (34095, Pierce
biotechnology Inc., Rockford, IL) using X-ray films (Denville
Scientific Inc., Metuchen, NJ).
Luciferase Assay Analysis
Cells were plated at 2610
5 in a 12-well plate in growth medium.
Cells were transfected in triplicate with 1.8 ug of luciferase plasmid
DNA and 0.2 ug of pCMV-Renilla (Promega). For cells treated
with anti-Dicer siRNA, 100 nM siRNA was transfected together
with Luciferase and Renilla using Amaxa nucleofection and collected
and analyzed 48 hours later. Cells at varying densities were
transfected using Amaxa nuclefection and 1.67610
5 cells (low) or
6.25610
5 cells (high) were plated in triplicate in a 12-well plate.
Cells treated with meBIO or BIO (1 mM) were transfected in
triplicate using Fugene6 (Roche). 24 hours after transfection, cells
were treated with either BIO or meBIO. 48 hours after treatment
cells were collected. In all cases, cells were lysed using passive lysis
Regulation of Cadherin-11
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(Promega). 20 ml of each sample was loaded in duplicate in a 96-
well plate and analyzed using the Dual-Luciferase Reporter Assay
System reagents (E1960, Promega). The plate was read on a
Berthold MicroLumat Plus LB 96V (Germany) using WinGlow
software (Berthold).
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